• Cadrenal Therapeutics CEO and Chairman Quang X. Pham sold 12,763 common shares in May at weighted-average prices of $4.93 to $5.76.
• Direct holdings fell to 182,161 shares following the latest sale on May 28.
• He also reported 200,000 shares held indirectly through The PVBQ Living Trust.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-062862), on May 29, 2026, and is solely responsible for the information contained therein.